Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
90Y-HAT for CD25+ Lymphoid Malignancies
NCT00001575Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Apr 1997
- Primary completion
- Nov 2013
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of yttrium-90 anti-Tac antibody in Hodgkin lymphoma (HL), non-Hodgkin lymphoma (NHL), lymphoid leukemia, cutaneous T-cell lymphoma (CTCL), peripheral T-cell lymphoma (PTCL), sponsored by National Cancer Institute. Started Apr 1997; status: completed.
02
Drugs
yttrium-90 anti-Tac antibody
03
Conditions
Hodgkin lymphoma (HL)non-Hodgkin lymphoma (NHL)lymphoid leukemiacutaneous T-cell lymphoma (CTCL)peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT00001575.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00001575.